NEJM· @NEJM · X·· 1 小时前精选AI 评分70
AI 导读
III 期 INDIGO 试验中，obexelimab 在 IgG4 相关疾病患者中较安慰剂降低了疾病复发风险。与安慰剂相比，obexelimab 组的糖皮质激素使用更低，缓解发生率更高。完整试验结果与研究摘要见 https://nej.md/4fKYQG4。
推荐理由
III 期 INDIGO 试验显示 obexelimab 较安慰剂降低 IgG4 相关疾病复发风险，读者可了解该在研药物的关键疗效与激素使用数据。
正文
In the phase 3 INDIGO trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. Full trial results and Research Summary: https://nej.md/4fKYQG4
来源：NEJM · x.com